Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma

Yu Qin, Jennifer R. Wang, Ying Wang, Priyanka Iyer, Gilbert J. Cote, Naifa L. Busaidy, Ramona Dadu, Mark Zafereo, Michelle D. Williams, Renata Ferrarotto, G. Brandon Gunn, Peng Wei, Keyur Patel, Marie Claude Hofmann, Maria E. Cabanillas

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Background: Anaplastic thyroid carcinoma (ATC) is an aggressive thyroid cancer that requires a rapid diagnosis and treatment to achieve disease control. Gene mutation profiling of circulating cell-free DNA (cfDNA) in peripheral blood may help to facilitate early diagnosis and treatment selection. The relatively rapid turnaround time compared with conventional tumor mutation testing is a major advantage. The objectives of this study were to examine the concordance of ATC-related mutations detected in cfDNA with those detected in the corresponding tumor tissue, and to determine the prognostic significance of cfDNA mutations in ATC patients. Methods: The ATC patients who were diagnosed and treated at The University of Texas MD Anderson Cancer Center between January 2015 and February 2018 and who had cfDNA testing were included in this study. cfDNA was collected by blood draw and was analyzed by next-generation sequencing (NGS) using the Guardant360-73 gene platform. Results: A total of 87 patients were included in the study. The most frequently mutated genes detected in cfDNA were TP53, BRAF, and PIK3CA. In 28 treatment naive ATC patients, the concordance rate of detected mutations in TP53, BRAFV600E, and PIK3CA between cfDNA and matched tissue NGS was 82.1%, 92.9%, and 92.9%, respectively. Patients with a PIK3CA mutation detected on cfDNA had worse overall survival (OS) (p = 0.03). This association was observed across various treatment modalities, including surgery, cytotoxic chemotherapy, radiation, and BRAF inhibitor (BRAFi) therapy. With regard to treatment, BRAFi therapy significantly improved ATC OS (p = 0.003). Conclusions: cfDNA is a valuable tool to evaluate a tumor's molecular profile in ATC patients. We identified high concordance rates between the gene mutations identified via cfDNA analysis and those identified from the NGS of the corresponding tumor tissue sequencing. Identified mutations in cfDNA can potentially provide timely information to guide treatment selection and evaluate the prognosis in patients with ATC.

Original languageEnglish (US)
Pages (from-to)1235-1243
Number of pages9
JournalThyroid
Volume31
Issue number8
DOIs
StatePublished - Aug 2021
Externally publishedYes

Keywords

  • BRAF inhibitor
  • PIK3CA
  • anaplastic thyroid carcinoma
  • cell free DNA
  • prognosis

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint

Dive into the research topics of 'Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma'. Together they form a unique fingerprint.

Cite this